Skip to content

PUSHING THE BOUNDARIES

At Kodiak, we are working to develop disruptive technologies and products to prevent and treat the leading causes of blindness

ABCD PLATFORM


Our Antibody Biopolymer Conjugate Drug (ABCD) Platform is at the heart of our portfolio of next generation retinal medicines

A PRODUCT PLATFORM ENABLING MULTI-MECHANISM THERAPIES EMPOWERED FOR DURABILITY


The ABCD Platform is purposefully designed for durability and powered to combine multiple modalities, such as proteins and other Active Pharmaceutical Ingredients (“API”) at a high drug-to-antibody ratio, in a single therapeutic

Explore the unique components of the ABCD Platform:

particle antibody-pointer
particle biopolymer-pointer
conjugate drug-pointer
conjugate conjugate-pointer conjugate-pointer-mobile

Engineered to exhibit high binding affinity and specificity. It can be any protein therapeutic, such as a monospecific or bispecific antibody.

Engineered to exhibit high binding affinity and specificity. It can be any protein therapeutic, such as a monospecific or bispecific antibody.

Conjugated to the biopolymer via a stable, site-specific linkage.

A bioinspired polymer that is engineered to make medicines last longer and extend their therapeutic benefit. It is also powered to combine multiple modalities.

A bioinspired polymer that is engineered to make medicines last longer and extend their therapeutic benefit. It is also powered to combine multiple modalities.

The biopolymer is optically clear and made of phosphorylcholine, the primary hydrophilic component of human cell membranes. It creates a water force field around the protein therapeutic without obstructing the binding sites, shielding it from non-specific interactions and providing greater on-target potency.

Small molecules and other bioactive molecules at a high drug-to-antibody (DAR) ratio can be embedded and released over time to enable treatment of complex, multifactorial diseases.

Small molecules and other bioactive molecules at a high drug-to-antibody (DAR) ratio can be embedded and released over time to enable treatment of complex, multifactorial diseases.

Enables the use of mechanistic bioactive molecules versus today’s Antibody Drug Conjugates (ADCs) whose low DAR limits use to cytotoxic agents.

A single therapeutic purposefully designed for durability and powered to combine multiple modalities for complex ocular and systemic diseases.

More than the sum of its parts

A single therapeutic purposefully designed for durability and powered to combine multiple modalities for complex ocular and systemic diseases.

Ursus, Kodiak’s custom commercial scale manufacturing facility designed for complex antibody conjugate biotherapies, is successfully commissioned as a cGMP facility for Kodiak’s ABC medicines.

SEE THE ABCD PLATFORM IN ACTION


The ABCD Platform is inspired by nature and designed with water in mind. Travel through the eye to see how ABCD medicines are engineered for increased durability and efficacy

square

The ABC Platform uses a bio-inspired polymer to orchestrate water around the antibody without obstructing the binding sites, preventing non-specific interactions

square

The ABC molecule can slip through crowded or tight areas like retina tissue, that would otherwise impede it

square

The high lubricity of the ABC molecule allows it to have ultra low friction, enabling it to penetrate tissues

square

Water influences antibody potency, enabling the ABC molecule to bind to its target with high affinity and specificity

Follow the water: launch the ABCD digital experience

MORE THAN THE SUM OF ITS PARTS


The ABCD Platform structures water at critical binding interfaces to make medicines last longer in the eye and improve their therapeutic benefit

Extended Intraocular Half-life

Medicines built on the ABCD Platform (e.g., tarcocimab tedromer) last longer and better maintain therapeutic concentration levels in the eye

Excellent Retinal Bioavailability

The ABCD Platform improves therapeutic absorption and distribution in the eye

Deeper Inhibitory Potency

The ABCD Platform shields the antibody from non-specific binding thereby providing greater on-target potency

Fast Systemic Clearing

Medicines built on the ABCD Platform are designed to clear the body quickly after exiting the eye

TAKE A 3-DIMENSIONAL TOUR


Tour our Antibody Biopolymer Conjugate (ABC) PlatformTM in 360° below.

Click and drag to see different views. Scroll or pinch to zoom.

Please be patient while the 3-D model loads

Launch the ABC Platform Interactive Experience